Immunization with pneumococcal surface protein K of nonencapsulated Streptococcus pneumoniae provides protection in a mouse model of colonization

Clinical and Vaccine Immunology

Volumn 22, Issue 11, 2015, Pages 1146-1153

  Keller, Lance E ^a   Luo, Xiao ^a   Thornton, Justin A ^b   Seo, Keun Seok ^c   Moon, Bo Youn ^c   Robinson, D Ashley ^a   McDaniel, Larry S ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PNEUMOCOCCAL SURFACE PROTEIN K; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIUM ANTIBODY; CYTOKINE; PNEUMOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; CELL ADHESION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUCOSAL IMMUNITY; NASOPHARYNX; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; CHEMISTRY; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; MICROBIOLOGY; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL PROTEINS; CELL ADHESION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; MICE; NASOPHARYNX; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; VIRULENCE FACTORS;

EID: 84945540652     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00456-15     Document Type: Article

References (49)

1. van Panhuis WG, Grefenstette J, Jung SY, Chok NS, Cross A, Eng H, Lee BY, Zadorozhny V, Brown S, Cummings D, Burke DS. 2013. Contagious diseases in the United States from 1888 to the present. N Engl J Med 369: 2152-2158. http://dx.doi.org/10.1056/NEJMms1215400.
2. Musher DM. 1992. Infections caused by Streptococcus pneumoniae: Clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 14: 801-809. http://dx.doi.org/10.1093/clinids/14.4.801.
3. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19: 187-195. http://dx.doi.org/10.1097/00006454-200003000-00003.
4. Calix JJ, Porambo RJ, Brady AM, Larson TR, Yother J, Abeygunwardana C, Nahm MH. 2012. Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae serotype 20 strains: Discovery of a new pneumococcal serotype. J Biol Chem 287: 27885-27894. http://dx.doi.org/10.1074/jbc.M112.380451.
5. Sa-Leao R, Nunes S, Brito-Avo A, Frazao N, Simoes AS, Crisostomo MI, Paulo AC, Saldanha J, Santos-Sanches I, de Lencastre H. 2009. Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol Infect 15: 1002-1007. http://dx.doi.org/10.1111/j.1469 -0691.2009.02775.x.
6. Croney CM, Nahm MH, Juhn SK, Briles DE, Crain MJ. 2013. Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following use of conjugate vaccine. Clin Vaccine Immunol 20: 1711-1718. http://dx.doi.org/10.1128/CVI.00381-13.
7. Valentino MD, McGuire AM, Rosch JW, Bispo PJM, Burnham C, Sanfilippo CM, Carter RA, Zegans ME, Beall B, Earl AM, Tuomanen EI, Morris TW, Haas W, Gilmore MS. 2014. Unencapsulated Streptococcus pneumoniae from conjunctivitis encode variant traits and belong to a distinct phylogenetic cluster. Nat Commun 5: 5411. http://dx.doi.org/10.1038/ncomms6411.
8. Xu Q, Kaur R, Casey JR, Sabharwal V, Pelton S, Pichichero ME. 2011. Nontypeable Streptococcus pneumoniae as an otopathogen. Diagn Microbiol Infect Dis 69: 200-204. http://dx.doi.org/10.1016/j.diagmicrobio .2010.09.019.
9. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE. 2002. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 70: 2526-2534. http://dx.doi.org/10.1128/IAI.70.5.2526-2534.2002.
10. Glover DT, Hollingshead SK, Briles DE. 2008. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun 76: 2767-2776. http://dx.doi.org/10 .1128/IAI.01126-07.
11. McDaniel LS, Sheffield JS, Delucchi P, Briles DE. 1991. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 59: 222-228.
12. Wu H-Y, Nahm MH, Guo Y, Russell MW, Briles DE. 1997. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175: 839-846. http://dx.doi.org/10.1086/513980.
13. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, Paton JC. 2000. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68: 3028-3033. http://dx.doi.org/10.1128/IAI .68.5.3028-3033.2000.
14. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. 2007. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 75: 350-357. http://dx.doi.org/10.1128/IAI.01103-06.
15. Keller LE, Thomas JC, Luo X, Nahm MH, McDaniel LS, Robinson DA. 2013. Draft genome sequences of five multilocus sequence types of nonencapsulated Streptococcus pneumoniae. Genome Announc 1(4): E00520-13.
16. Tavares D, Simoes A, Bootsma H, Hermans P, de Lencastre H, Sa-Leao R. 2014. Non-Typeable pneumococci circulating in Portugal are of cps type NCC2 and have genomic features typical of encapsulated isolates. BMC Genomics 15: 863. http://dx.doi.org/10.1186/1471-2164-15-863.
17. Bergmann S, Hammerschmidt S. 2006. Versatility of pneumococcal surface proteins. Microbiology 152: 295-303. http://dx.doi.org/10.1099/mic .0.28610-0.
18. Hammerschmidt S. 2006. Adherence molecules of pathogenic pneumococci. Curr Opin Microbiol 9: 12-20. http://dx.doi.org/10.1016/j .mib.2005.11.001.
19. Keller LE, Friley J, Dixit C, Nahm MH, McDaniel LS. 2014. Nonencapsulated Streptococcus pneumoniae cause acute otitis media in the chinchilla that is enhanced by pneumococcal surface protein K. Open Forum Infect Dis 1(2): Ofu037. http://dx.doi.org/10.1093/ofid/ofu037.
20. Keller LE, Jones CV, Thornton JA, Sanders ME, Swiatlo E, Nahm MH, Park IH, McDaniel LS. 2013. PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization. Infect Immun 81: 173-181. http://dx.doi.org/10.1128/IAI.00755-12.
21. Park IH, Kim KH, Andrade AL, Briles DE, McDaniel LS, Nahm MH. 2012. Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. mBio 3(3): E00035-12.
22. Dave S, Carmicle S, Hammerschmidt S, Pangburn MK, McDaniel LS. 2004. Dual roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory IgA and factor H. J Immunol 173: 471-477. http://dx.doi.org/10.4049/jimmunol.173.1.471.
23. Graham RMA, Paton JC. 2006. Differential role of CbpA and PspA in modulation of in vitro CXC chemokine responses of respiratory epithelial cells to infection with Streptococcus pneumoniae. Infect Immun 74: 6739-6749. http://dx.doi.org/10.1128/IAI.00954-06.
24. Durand SH, Flacher V, Roméas A, Carrouel F, Colomb E, Vincent C, Magloire H, Couble M-L, Bleicher F, Staquet M-J, Lebecque S, Farges J-C. 2006. Lipoteichoic acid increases TLR and functional chemokine expression while reducing dentin formation in in vitro differentiated human odontoblasts. J Immunol 176: 2880-2887. http://dx.doi.org/10.4049/jimmunol.176.5.2880.
25. Medzhitov R, Janeway C, Jr. 2000. Innate immune recognition: Mechanisms and pathways. Immunol Rev 173: 89-97. http://dx.doi.org/10.1034/j.1600-065X.2000.917309.x.
26. Verhoef J, Mattsson E. 1995. The role of cytokines in gram-positive bacterial shock. Trends Microbiol 3: 136-140. http://dx.doi.org/10.1016/S0966-842X(00)88902-7.
27. Yoshie O, Imai T, Nomiyama H. 2001. Chemokines in immunity. Adv Immunol 78: 57-110. http://dx.doi.org/10.1016/S0065-2776(01)78002-9.
28. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686. http://dx.doi.org/10.1016/j.it .2004.09.015.
29. Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Björck L, Meri S. 2002. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol 168: 1886-1894. http://dx.doi.org/10.4049/jimmunol.168.4.1886.
30. Gwaltney JM, Sande MA, Austrian R, Hendley JO. 1975. Spread of Streptococcus pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum antibody. J Infect Dis 132: 62-68.
31. Loda FA, Collier AM, Glezen WP, Strangert K, Clyde WA, Jr, Denny FW. 1975. Occurrence of Diplococcus pneumoniae in the upper respiratory tract of children. J Pediatr 87: 1087-1093. http://dx.doi.org/10.1016/S0022 -3476(75)80120-X.
32. Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, van Ginkel FW, Benjamin WH. 2003. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188: 339-348. http://dx.doi.org/10.1086/376571.
33. Avery OT, MacLeod CM, McCarty M. 1944. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 79: 137-158. http://dx.doi.org/10 .1084/jem.79.2.137.
34. Brooks-Walter A, Briles DE, Hollingshead SK. 1999. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun 67: 6533-6542.
35. He X, McDaniel LS. 2007. The genetic background of Streptococcus pneumoniae affects protection in mice immunized with PspA. FEMS Microbiol Lett 269: 189-195. http://dx.doi.org/10.1111/j.1574-6968.2006.00516.x.
36. + T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A 102: 4848-4853. http://dx.doi.org/10.1073/pnas.0501254102.
37. Park IH, Geno KA, Sherwood LK, Nahm MH, Beall B. 2014. Population-based analysis of invasive nontypeable pneumococci reveals that most have defective capsule synthesis genes. PLoS One 9(5): E97825. http://dx.doi.org/10.1371/journal.pone.0097825.
38. van Rossum AMC, Lysenko ES, Weiser JN. 2005. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect Immun 73: 7718-7726. http://dx.doi.org/10.1128/IAI.73.11.7718-7726.2005.
39. Zhang Z, Clarke TB, Weiser JN. 2009. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119: 1899-1909.
40. Magee AD, Yother J. 2001. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun 69: 3755-3761. http://dx.doi.org/10.1128/IAI.69.6.3755-3761.2001.
41. Nelson AL, Roche AM, Gould JM, Chim K, Ratner AJ, Weiser JN. 2007. Capsule enhances pneumococcal colonization by limiting mucusmediated clearance. Infect Immun 75: 83-90. http://dx.doi.org/10.1128/IAI.01475-06.
42. Allegrucci M, Hu FZ, Shen K, Hayes J, Ehrlich GD, Post JC, Sauer K. 2006. Phenotypic characterization of Streptococcus pneumoniae biofilm development. J Bacteriol 188: 2325-2335. http://dx.doi.org/10.1128/JB .188.7.2325-2335.2006.
43. Allegrucci M, Sauer K. 2008. Formation of Streptococcus pneumoniae non-phase-variable colony variants is due to increased mutation frequency present under biofilm growth conditions. J Bacteriol 190: 6330-6339. http://dx.doi.org/10.1128/JB.00707-08.
44. Waite RD, Struthers JK, Dowson CG. 2001. Spontaneous sequence duplication within an open reading frame of the pneumococcal type 3 capsule locus causes high-frequency phase variation. Mol Microbiol 42: 1223-1232.
45. Kang HY, Srinivasan J, Curtiss R. 2002. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar Typhimurium vaccine. Infect Immun 70: 1739-1749. http://dx.doi.org/10.1128/IAI.70.4.1739-1749.2002.
46. Khan AQ, Shen Y, Wu Z-Q, Wynn TA, Snapper CM. 2002. Endogenous pro-And anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus pneumoniae. Infect Immun 70: 749-761. http://dx.doi.org/10.1128/IAI.70.2.749-761.2002.
47. Yamamoto M, McDaniel LS, Kawabata K, Briles DE, Jackson RJ, McGhee JR, Kiyono H. 1997. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun 65: 640-644.
48. McEllistrem MC, Nahm MH. 2012. Novel pneumococcal serotypes 6C and 6D: Anomaly or harbinger. Clin Infect Dis 55: 1379-1386. http://dx.doi.org/10.1093/cid/cis691.
49. Oliver MB, van der Linden MPG, Küntzel SA, Saad JS, Nahm MH. 2013. Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem 288: 25976-25985. http://dx.doi.org/10.1074/jbc.M113.480152.